Show
Sort by
-
Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers
-
CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam
-
Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2 cohort B 18-month follow-up
-
RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study
-
Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial
-
Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study
-
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma
-
Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma
-
Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial
-
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma
-
Mutational permutations of a single amino acid exert divergent phenotypic effects in human, mice and cellular models of SAMD9L bone marrow failure disorder
-
ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey
-
- Journal Article
- A1
- open access
Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics and DNA repair
-
SOX11 functions as an oncogene in Lmo2-driven T-cell lymphoblastic leukemia (T-ALL)
-
Association of unbalanced translocation der(1;7) with germline GATA2 mutations
-
Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells
-
CAR-T treatment of pediatric AML : a long and winding road
-
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
-
T-ALL and the talented Mr IL7R alpha
-
Chemotherapy at the wheel of ALL relapse
-
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma
-
- Conference Paper
- C3
- open access
NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia : a good prognostic subtype identified in a collaborative international study
-
- Conference Paper
- C3
- open access
Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia
-
Results from the phase I clinical studies evaluating Cyad-01, a first-generation NKG2D CAR T-cell product in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
Transplantation for congenital sideroblastic anaemia is feasible and offers outcomes comparable to other transfusion dependent anaemias : a joint retrospective study of the paediatric diseases and severe aplastic anaemia working parties (PDWP/SAAWP) of EBMT
-
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer : a study of the chronic malignancies working party of the EBMT
-
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma : interim analysis of the phase 2 ELARA trial
-
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the niveau trial
-
Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the sadal pivotal study
-
Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma
-
Selinexor efficacy and safety are independent of renal function in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis from the pivotal phase 2b sadal study
-
- Journal Article
- A1
- open access
The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation
-
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura
-
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1
-
CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody Atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma
-
- Conference Paper
- C3
- open access
Results from the completed dose-escalation of the hematological arm of the Phase I Think Study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse/refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
Implication of inherited genetic variants associated with follicular lymphoma susceptibility in the prognosis of patients treated by immunochemotherapy in PRIMA study
-
Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma : preliminary results from a phase Ib trial
-
- Conference Paper
- C3
- open access
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapse or refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
Exploring the potential of shallow whole-genome sequencing for diagnosis and disease monitoring of lymphoma in liquid biopsy
-
The exosomal transfer of acid sphingomyelinase contributes to drug resistance in multiple myeloma
-
Effect of prior therapy on the efficacy and safety of oral Selinexor in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study
-
Response to therapy and the effectiveness of treatment with Selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas
-
Deciphering molecular heterogeneity in pediatric AML using a cancer vs normal transcriptomic approach
-
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia : proof of concept study
-
Ixazomib, Rituximab and Dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinemia : results of the prospective phase I/II hovon 124/Ecwm-R2 trial
-
Phase 2 results of the iR(2) Regimen (Ibrutinib, Lenalidomide, and Rituximab) in patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
-
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival
-
Priority lane to cDC1 open for IRF8⁺ progenitors
-
PHF6 : it is written in the stem cells
-
Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation : a multicenter prospective study
-
- Conference Paper
- C3
- open access
Proteasome inhibition by carfilzomib impairs terminal erythroid maturation and causes reticulocytosis in patients with multiple myeloma
-
Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial
-
CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial
-
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma
-
The iR(2) regimen (ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma
-
Characterization of the long-term efficacy and safety of duvelisib monotherapy in patients with relapsed/refractory CLL/SLL on treatment for > 2 years across 4 clinical studies
-
Remissions in relapse/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy
-
Haploidentical transplantation using high dose post-transplant cyclophosphamide for patients with aplastic anemia : the European Group for Blood and Marrow Transplantation experience
-
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
-
RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
-
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML : a retrospective study by the I-BFM Study Group
-
Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, Cyad-01, in acute myeloid leukemia
-
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis
-
The Medalist trial : results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions
-
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia
-
Darbepoetin alfa for the treatment of anemic patients with myelodysplastic syndrome : a Belgian single-arm, companion trial to the Arcade phase 3 study
-
Real world outcome in a patient cohort with newly diagnosed diffuse large B cell lymphoma
-
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling
-
Highly variable frequencies of donor antigen-specific naive cells may dictate the immunogenicity of minor histocompatibility antigens after hematopoietic stem cell transplantation
-
Novel oncogenic noncoding mutations in T-ALL
-
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years
-
Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
-
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
-
Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL)
-
Unique long non-coding RNA expression signature in ETV6/RUNX1-Driven B-cell precursor acute lymphoblastic leukemia
-
Genomic landscape of pediatric mixed phenotype acute leukemia
-
Impact of age and treatment group in childhood high hyperdiploid low risk B-cell acute lymphoblastic leukemia (ALL) : results of the CLG-EORTC 58951 study
-
RPPA-Based protein profiling reveals enhanced PI3K/AKT/mTOR signaling in ETV6/RUNX1-positive acute lymphoblastic leukemia patients with low CD200 expression
-
A novel multiplex NGS-based digital MLPA assay for copy number detection of 700 target sequences in childhood acute lymphoblastic leukemia
-
Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia
-
IFM2012-03
-
Impact of somatic mutations on the outcome of children and adolescents with therapy-related myelodysplastic syndrome
-
Prognostic discrimination of children and adolescents with chronic myeloid leukemia based on the EUTOS Long Term Survival (ELTS) score
-
Oncogenic ZEB2 activation drives sensitivity towards LSD1 inhibition in T-Cell acute lymphoblastic leukemia
-
Therapeutic targeting of the histone ubiquitination-methylation axis in T cell leukemia
-
Cyclin D2 overexpression recapitulates mantle cell lymphoma in mice
-
PRC2 mutations induce resistance to conventional chemotherapy by inhibiting mitochondrial apoptosis in T-cell acute lymphoblastic leukemia
-
The checkpoint for agonist selection precedes conventional selection in human thymus
-
Macrophage precursors PLASTed INto alveolar space
-
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia
-
Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents
-
Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors
-
Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation : an international multicenter study
-
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study
-
Clonal mutational landscape of childhood myelodysplastic syndromes
-
The relevance of stem cell load at diagnosis for the development of relapse in pediatric acute myeloid leukemia
-
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics
-
Switch to subsequent line of treatment in children and adolescents with chronic myeloid leukemia (CML) treated with imatinib : experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped study)